Using remimazolam combined with sufentanil

Background: Hysteroscopy, the gold standard for diagnosing and treating intrauterine pathologies, has shown substantial increase in its adoption in clinical practice. Nevertheless, early postoperative pain and opioid-related adverse effects remain critical determinants of recovery quality. Oliceridine—a novel G protein-biased μ-opioid receptor agonist—demonstrates an improved therapeutic range over conventional opioids in preliminary studies. Objective: This #Study aims to evaluate whether oliceridine enhances recovery quality while reducing opioid-related complications compared to sufentanil in patients undergoing hysteroscopy under general anesthesia. Methods: This single-center #RCT #ClinicalTrial will enroll 120 patients undergoing hysteroscopy under general anesthesia with 1:1 randomization to sufentanil- or oliceridine-based analgesia. The primary outcome is early recovery quality assessed by the 15-item Quality of Recovery scale at 24 hours after the surgery, while secondary outcomes include hemodynamic fluctuations during induction, total intraoperative opioid consumption and supplemental bolus frequency, proportion requiring vasoactive agents, incidence of respiratory depression in postanesthesia care unit, postoperative extubation time, opioid-related adverse events within 24 hours, and Visual Analog Scale pain scores at 30 minutes, 4 hours, 8 hours, and 24 hours postextubation. Results: This #Study received approval from the Medical Ethics Committee of Deyang People’s Hospital, Deyang, China, on April 16, 2025 (approval 2025-03-009-K01). Participant recruitment is anticipated to be completed by December 2025. Data analysis, manuscript preparation, and submission for publication are expected to be completed by February 2026. Conclusions: The successful completion of this trial will generate evidence regarding whether oliceridine enhances recovery quality while reducing opioid-related complications compared to sufentanil in patients undergoing hysteroscopy under general anesthesia. Trial Registration: Chinese Clinical Trial Registry ChiCTR2500104024; https://www.chictr.org.cn/showproj.html?proj=275501

Chemicals Compounds were obtained from the following vendors: Sigma-Aldrich: oxymorphone (O-004-1ML), loperamide (1448005), methadone hydrochloride (M0267), morphine sulfate pentahydrate (M8777), sufentanil citrate (SML0535), herkinorin (5.08018.0001), buprenorphine (B9275), serotonin hydrochloride (H9523), carbachol (C4382), naloxone hydrochloride (N7758) and GDP (G7127). Cayman Chemical: PZM21 (20576-10), fentanyl citrate (22659) and GTPγS (35098). DAMGO (11711) was from Tocris Bioscience. Oliceridine (TRV-130; 510256) was from MedKoo Biosciences.

For the combined spinal epidural analgesia for labour, 30 mcg of subarachnoid clonidine has proved its effectiveness to extend the analgesia, but increased severe hemodynamic effects. To assess the effectiveness and the safety of 15 mcg int...

For the combined spinal epidural analgesia for labour, 30 mcg of subarachnoid clonidine has proved its effectiveness to extend the analgesia, but increased severe hemodynamic effects. To assess the effectiveness and the safety of 15 mcg int...

Evaluating the efficacy and safety of patient-controlled intravenous analgesia regimen combining sufentanil and dezocine versus sufentanil alone for postop pain

Evaluating the efficacy and safety of patient-controlled intravenous analgesia regimen combining sufentanil and dezocine versus sufentanil alone for postop pain

A total of 480 patients who underwent painless GI endoscopy from November 7, 2022, to April 14, 2023, were recruited. And 318 patients were screened for

Purpose This randomised controlled trial investigated the effect of Surgical Pleth Index (SPI) guided sufentanil administration on intraoperative sufentanil consumption compared to routine care in patients with a combination of general anaesthesia and regional anaesthesia having trauma and orthopaedic surgery. Methods Eighty patients with a combination of general anaesthesia and regional anaesthesia undergoing trauma or orthopaedic surgery were randomised into two groups to receive either sufentanil guided by SPI monitoring or by routine care (Control). The primary endpoint was intraoperative sufentanil consumption. Secondary endpoints were postoperative pain level, opioid consumption, incidence of nausea, duration of time in the post-anaesthesia care unit (PACU) and quality of recovery. Results The median intraoperative sufentanil administration adjusted to bodyweight and surgery duration did not differ between the groups: SPI guided group 2.29 (interquartile range, IQR 0.29 to 6.91), Control 1.65 (IQR 0.83 to 2.63) µg·kg−1·min−1*1000 (P = 0.906). The relative risk for receiving intraoperative sufentanil was RR 0.909 (95% CI 0.723 to  1.143, P = 0.414). Median morphine equivalents administered in the 24 h after discharge from the PACU were 3.8 (IQR 0.0 to 22.5) in the SPI guided group and 19.1 (IQR 3.8 to 30.0) mg (P = 0.021) in the control group without adjustment for multiple testing. Other secondary endpoints showed no differences. Conclusion SPI guided sufentanil administration did not reduce intraoperative sufentanil consumption compared to routine care in patients having trauma and orthopaedic surgery with a combination of general anaesthesia and regional anaesthesia. Trial registration Clinicaltrials.gov identifier NCT06040307 (registered September 8, 2023).

Date Submitted: Sep 21, 2025. Open Peer Review Period: Sep 22, 2025 - Nov 17, 2025.

Date Submitted: Sep 21, 2025. Open Peer Review Period: Sep 22, 2025 - Nov 17, 2025.